Innovation Investment Fund (IIF)

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Vaxxas has finished enrolling 258 volunteers in its Phase I trial of a needle-free HD-MAP avian flu vaccine, funded by a US BARDA contract, with early findings due mid-2025.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas has won the concept stage of BARDA's Patch Forward Prize, earning US$2 million (A$3.2 million) to progress its microarray patch vaccine platform alongside the University of Queensland's BASE facility.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches

Vaxxas has exclusively licensed UT Austin's HexaPro spike protein for a needle-free COVID-19 vaccine patch, backed by an NIH license, with a Phase 1 trial planned this year; background notes its founding backers.

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period

Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

Vaxxas has received a US$22 million (A$30.6 million) US government BARDA award to advance its needle-free vaccine patch for pandemic use; earlier financing led by OneVentures with Brandon Capital is recalled.

GBS Ventures completes healthcare fund with global first quartile performance

GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.